Funding for this research was provided by:
Sanitätsakademie der Bundeswehr
Received: 3 June 2022
Accepted: 9 June 2022
First Online: 11 July 2022
: CDS reports grants and personal fees from AbbVie, grants, fees, and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, grants and personal fees from MSD, grants from Cepheid, personal fees from GSK, and grants and personal fees from ViiV Healthcare, during the conduct of the study; fees from AstraZeneca, other from Apeiron, grants, personal fees and non-financial support from BBraun Melsungen, grants, personal fees from BioNtech, personal fees from Eli Lilly, personal fees from Formycon, personal fees from Molecular partners, grants and personal fees from Eli Lilly, personal fees from Roche, and personal fees from SOBI. All other authors declared no conflicts of interest.
: All patients provided informed consent to the use of their data and clinical samples for the purposes of the present study. Institutional review board clearance for the scientific use of patient data and samples has been granted to the treating institution by the ethics committee at the Medical Faculty of the Ludwig-Maximilian University (LMU) of Munich (vote 22-0493).